Literature DB >> 18832477

Absolute difference of hepatobiliary transporter multidrug resistance-associated protein (MRP2/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human.

Na Li1, Yiqun Zhang, Fengmei Hua, Yurong Lai.   

Abstract

We previously reported that hepatobiliary transporter multidrug resistance-associated protein (MRP2/Mrp2) is considered to be the major cause of the interspecies differences detected by efflux of fluorescent substrates in isolated hepatocytes. In the present study, the interspecies differences of MRP2/Mrp2 were first evaluated by quantitative real-time polymerase chain reaction and Western blotting. The mRNA levels were able to distinguish the difference among species with a rank order comparable with the corresponding activities observed, whereas the extents of the differences remained unknown. The cross-reactions of MRP2/Mrp2 protein of different species with anti-human MRP2 polyclonal antibody were found by Western blotting. However, because of the unknown binding affinity of antibody to MRP2/Mrp2 protein across species and lack of purified MRP2/Mrp2 proteins for calibration, the immunoblotting assay was excluded from the absolute quantification of MRP2/Mrp2 protein for multiple species. By using our newly developed liquid chromatography-tandem mass spectrometry quantification method, we were able to measure the absolute amount of MRP2/Mrp2 in liver tissues and isolated hepatocytes across species. Freshly isolated hepatocytes conserved MRP2/Mrp2 protein levels that are comparable with those in the liver tissues. The amount of Mrp2 in rat liver was approximately 10-fold higher than that in other species. Moreover, a significant loss of Mrp2 protein in the membrane fraction of rat cryopreserved hepatocytes was observed. Thus, the absolute differences of MRP2/Mrp2 levels in various species were determined, for the first time, by direct quantification. The results could potentially fill the translational gaps of in vitro/in vivo or preclinical species to human extrapolation of hepatobiliary elimination mediated by MRP2/Mrp2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832477     DOI: 10.1124/dmd.108.023234

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  21 in total

1.  From the Cover: Three-Dimensional (3D) HepaRG Spheroid Model With Physiologically Relevant Xenobiotic Metabolism Competence and Hepatocyte Functionality for Liver Toxicity Screening.

Authors:  Sreenivasa C Ramaiahgari; Suramya Waidyanatha; Darlene Dixon; Michael J DeVito; Richard S Paules; Stephen S Ferguson
Journal:  Toxicol Sci       Date:  2017-09-01       Impact factor: 4.849

2.  Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes.

Authors:  Nathan D Pfeifer; Kyunghee Yang; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2013-09-10       Impact factor: 4.030

3.  Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry.

Authors:  Anand K Deo; Bhagwat Prasad; Larissa Balogh; Yurong Lai; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2012-02-08       Impact factor: 3.922

4.  Targeted precise quantification of 12 human recombinant uridine-diphosphate glucuronosyl transferase 1A and 2B isoforms using nano-ultra-high-performance liquid chromatography/tandem mass spectrometry with selected reaction monitoring.

Authors:  John K Fallon; Hendrik Neubert; Theunis C Goosen; Philip C Smith
Journal:  Drug Metab Dispos       Date:  2013-09-17       Impact factor: 3.922

5.  Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS.

Authors:  John K Fallon; Philip C Smith; Cindy Q Xia; Mi-Sook Kim
Journal:  Pharm Res       Date:  2016-06-29       Impact factor: 4.200

Review 6.  The role of transporters in the pharmacokinetics of orally administered drugs.

Authors:  Sarah Shugarts; Leslie Z Benet
Journal:  Pharm Res       Date:  2009-06-30       Impact factor: 4.200

7.  Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data.

Authors:  Agnès Poirier; Anne-Christine Cascais; Christoph Funk; Thierry Lavé
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-20       Impact factor: 2.745

8.  Comment on the article "physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions".

Authors:  Sibylle Neuhoff; Geoff T Tucker
Journal:  Pharm Res       Date:  2013-03-16       Impact factor: 4.200

Review 9.  Quantitative targeted proteomics for membrane transporter proteins: method and application.

Authors:  Xi Qiu; Hui Zhang; Yurong Lai
Journal:  AAPS J       Date:  2014-05-15       Impact factor: 4.009

Review 10.  Use of in vivo animal models to assess pharmacokinetic drug-drug interactions.

Authors:  Cuyue Tang; Thomayant Prueksaritanont
Journal:  Pharm Res       Date:  2010-04-29       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.